文献速递其他结缔组织病

益生菌对系统性硬化症胃肠道症状及免疫参数的影响:一项随机安慰剂对照试验

Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

这项随机安慰剂对照试验纳入73例中重度胃肠道症状的系统性硬化症患者,每日给予益生菌或安慰剂8周。结果显示两组UCLA GIT 2.0总分无差异,但益生菌组Th17细胞比例较安慰剂组显著下降(P=0.003),Th1、Th2、调节性T细胞及HAQ-DI评分无差异。

要点

  • 益生菌未改善系统性硬化症患者胃肠道症状。
  • 益生菌组Th17细胞比例较安慰剂组显著下降(P=0.003)。
  • Th1、Th2、调节性T细胞及HAQ-DI评分组间无差异。

核心结论

  • 益生菌未改善系统性硬化症患者的胃肠道症状。
  • Th17细胞水平下降提示益生菌对系统性硬化症具有免疫调节作用。

研究设计与样本

  • 随机安慰剂对照试验,纳入73例UCLA GIT 2.0总分为中重度的系统性硬化症患者,随机分为益生菌组(n=37)和安慰剂组(n=36)。
  • 益生菌组每日给予含副干酪乳杆菌、鼠李糖乳杆菌、嗜酸乳杆菌和乳双歧杆菌的胶囊,每粒109菌落形成单位,疗程8周。

主要发现

  • 治疗8周后,两组UCLA GIT 2.0评分无差异。
  • 第8周时,益生菌组Th17细胞比例较安慰剂组显著下降(P=0.003)。
  • 两组Th1、Th2和调节性T细胞比例及HAQ-DI评分无差异。

关键数值与推荐

  • 主要终点为治疗8周后UCLA GIT 2.0总评分的改善。
  • 次要结局包括Th1、Th2、Th17和调节性T细胞循环水平及HAQ-DI评分的变化,于基线、治疗4周和8周评估。

临床怎么用

  • 对于中重度胃肠道症状的系统性硬化症患者,益生菌不应作为改善胃肠道症状的常规推荐。
  • 益生菌对Th17细胞的调节作用提示其可能具有免疫调节潜力,但需进一步研究验证临床意义。

局限性

  • 样本量较小(共73例),可能影响结果的普遍性。
  • 干预时间仅8周,长期疗效未知。
  • 未报告胃肠道症状以外的临床结局变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Changes in the intestinal microbiota have been associated with the pathogenesis of SSc. Probiotics act by modulating the microbiome and the immune response. This study aimed to evaluate the efficacy of probiotics on gastrointestinal (GI) symptoms and immune responses in SSc patients. METHODS: Patients with SSc with a moderate-severe total score on the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA GIT 2.0) instrument were randomly assigned to receive a daily dose of probiotics (Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus and Bifidobacterium lactis, 109 colony-forming units per capsule) or placebo for 8 weeks. The primary endpoint was improvement in the UCLA GIT 2.0 total score after 8 weeks. Secondary outcomes included changes in Th1, Th2, Th17 and regulatory T cell circulating levels and in the HAQ Disability Index (HAQ-DI) score. Parameters were assessed at baseline and after 4 and 8 weeks of treatment. RESULTS: A total of 73 patients were randomized to receive probiotics (n = 37) or placebo (n = 36). After 8 weeks, there was no difference in the UCLA GIT 2.0 score between the two groups. At week 8, the probiotic group showed a significant decrease in the proportion of Th17 cells compared with placebo (P = 0.003). There was no difference in the proportion of Th1, Th2 and regulatory T cells or in the HAQ-DI score between the groups. CONCLUSION: Probiotics did not improve GI symptoms in SSc patients. The reduction in Th17 cell levels suggests an immunomodulatory effect of probiotics on SSc. TRIAL REGISTRATION: ClinicalTrials.gov (http://clinicaltrials.gov), NCT02302352.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Marighela TF, Arismendi MI, Marvulle V, et al. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial. Rheumatology (Oxford). 2019. PMID: 31056685. doi:10.1093/rheumatology/kez160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。